InvestmentJul 28, 2026, 04:18 PM
Entera Bio Raises $275M in Private Placement
AI Summary
Entera Bio Ltd. completed a private placement on July 28, 2026, raising approximately $275.0 million. The company issued an aggregate of 134,803,910 ordinary shares and pre-funded warrants to institutional and accredited investors, including funds affiliated with BVF Partners L.P., at a price of $2.04 per share. The net proceeds are intended to support the initiation of the company's phase 3 registrational study of EB613 in postmenopausal women with osteoporosis, as well as for general working capital and corporate purposes. BVF Partners L.P. also secured the right to designate two directors to Entera Bio's board.
Key Highlights
- Raised $275.0 million in a private placement.
- Issued 134,803,910 ordinary shares or pre-funded warrants.
- Shares priced at $2.04 per ordinary share.
- BVF Partners L.P. affiliated funds were key purchasers.
- Proceeds to fund Phase 3 registrational study of EB613 for osteoporosis.
- BVF granted right to designate two directors to the Board.
- Leerink Partners acted as lead placement agent.
Price Impact
More from ENTX